Related Experiment Video
Updated: Jun 4, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Epigenetic and genetic insights for tailored therapeutic strategies in multiple sclerosis
Aliakbar Mariki1, Seyed Mohammad Mousavi2, Kristi Anne Kohlmeier3
1Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
Abstract:
Multiple sclerosis (MS) is a complex neurological disorder with inflammation, demyelination, and neurodegeneration in the CNS. Disease-modifying therapies (DMTs) exist, but their efficacy is limited by MS's varied nature, highlighting the need for personalized treatments. From January 2009 to March 2025, a literature search across PubMed, Scopus, Web of Science, and Google Scholar identified over 200 multiple sclerosis (MS) genetic loci. HLA-DRB1*15:01 is a key genetic risk factor, alongside significant environmental contributors such as Epstein-Barr virus infection, smoking, and vitamin D deficiency. Epigenetic modifications, such as DNA methylation and non-coding RNAs, mediate the interaction between genetic predisposition and environmental factors. Altered methylation patterns in genes like FOXP3 and IL-10 disrupt immune regulation, exacerbating disease progression. Emerging biomarkers such as CHI3L1, miR-155, and IL-10 methylation patterns have shown potential for diagnosis and prognosis. Multi-omics strategies and artificial intelligence (AI) offer innovative solutions for integrating these biomarkers into clinical practice. Personalized therapy options, such as low-dose IL-2 and JAK-STAT pathway inhibitors, highlight the potential of precision medicine in enhancing treatment outcomes. This synthesis identifies inconsistencies and methodological limitations in current research, proposing a roadmap for pathway-specific therapies based on integrated genetic-epigenetic profiling.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Multiple Sclerosis l: Introduction
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
